info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Autoimmune Disease Treatment Companies

Acute care electronic health record (EHR) companies specialize in providing electronic health record systems specifically tailored for acute care settings such as hospitals, emergency departments, and urgent care facilities. These EHR systems are designed to support the unique needs of fast-paced, high-acuity environments where timely and accurate patient information is crucial

Autoimmune Disease Treatment Key Companies

 

Latest Autoimmune Disease Treatment Companies Update



Immunovant (IMVT) Soared nearly 100% after Phase 1 trial results of their injectable treatment, IMVT-1402, showed successful reduction in disease-causing antibodies. Phase 2 trials are planned for 2024.


AstraZeneca Announced positive Phase 3 data for their anti-IL-17A drug, brodalumab, showing significant improvement in psoriatic arthritis symptoms compared to placebo. Regulatory submissions are planned for 2024.


Eli Lilly Reported positive Phase 2b data for their JAK inhibitor, abrocitinib, in treating ulcerative colitis. They plan to initiate Phase 3 trials in 2024.


Pfizer Acquired Viavi Pharmaceuticals for $5.2 billion, gaining access to Viavi's late-stage lupus drug, atacicept. This strengthens Pfizer's autoimmune disease portfolio.


Roche and Gilead Formed a research collaboration to develop new treatments for inflammatory bowel disease. This combines expertise and resources to accelerate discoveries.


Sanofi and Kymab Partnered to develop and commercialize anti-inflammatory antibodies targeting IL-17C and IL-17A for various autoimmune diseases.


List of Autoimmune Disease Treatment Key Companies in the Market


• Abbott Laboratories


• Amgen Inc.


• Genentech Inc.


• Bayer Schering Pharma AG


• Biogen Idec Inc.


• Bio-Rad


• Chugai Pharmaceutical Co. Ltd.


• Danaher


• Elan Corporation Plc


• Eli Lilly and Company


• F. Hoffmann-La Roche AG


• GlaxoSmithKline Plc


• HYCOR Biomedical


• Johnson & Johnson Inc.


 


• Merck & Co. Inc.


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.